Status:
COMPLETED
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
Lead Sponsor:
Pfizer
Conditions:
Urinary Bladder, Overactive
Eligibility:
All Genders
65+ years
Phase:
PHASE4
Brief Summary
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently t...
Eligibility Criteria
Inclusion
- Male or female ≥65 years old.
- Overactive bladder symptoms for at least 3 months prior to study start.
- Eight or more micturitions per 24 hours as confirmed by diary records
Exclusion
- Predominant Stress Urinary Incontinence
- Active or recurrent bladder infections
- Other bladder and genital conditions that could be the predominant cause of symptoms or interfere with treatment assessment and success.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
794 Patients enrolled
Trial Details
Trial ID
NCT00798434
Start Date
June 1 2008
End Date
September 1 2010
Last Update
December 14 2011
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Vienna, Austria, 1090
2
Pfizer Investigational Site
Antwerp, Belgium, 2060
3
Pfizer Investigational Site
Edegem, Belgium, B-2650
4
Pfizer Investigational Site
Ghent, Belgium, B-9000